Attached files

file filename
EX-10.17 - EX-10.17 - ACHILLION PHARMACEUTICALS INCd115302dex1017.htm
EX-31.1 - EX-31.1 - ACHILLION PHARMACEUTICALS INCd115302dex311.htm
EX-10.25 - EX-10.25 - ACHILLION PHARMACEUTICALS INCd115302dex1025.htm
EX-23.1 - EX-23.1 - ACHILLION PHARMACEUTICALS INCd115302dex231.htm
EX-10.16 - EX-10.16 - ACHILLION PHARMACEUTICALS INCd115302dex1016.htm
EX-10.23 - EX-10.23 - ACHILLION PHARMACEUTICALS INCd115302dex1023.htm
EX-10.24 - EX-10.24 - ACHILLION PHARMACEUTICALS INCd115302dex1024.htm
10-K - FORM 10-K - ACHILLION PHARMACEUTICALS INCd115302d10k.htm
EX-32.1 - EX-32.1 - ACHILLION PHARMACEUTICALS INCd115302dex321.htm
EX-31.2 - EX-31.2 - ACHILLION PHARMACEUTICALS INCd115302dex312.htm

EXHIBIT 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report on Form 10-K of Achillion Pharmaceuticals, Inc. (the “Company”) for the period ended December 31, 2015 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Mary Kay Fenton, Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350 as adopted by Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: February 25, 2016

/s/    MARY KAY FENTON        

Mary Kay Fenton
Chief Financial Officer

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.